Observations placeholder

Paliperidone (trade name Invega), also known as 9-hydroxyrisperidone, is a dopamine antagonist and 5-HT2A antagonist of the atypical antipsychotic class of medications. It is marketed by Janssen Pharmaceutica. Invega is an extended release formulation of paliperidone that uses the OROS extended release system to allow for once-daily dosing.

Paliperidone palmitate (trade name Invega Sustenna, named Xeplion in Europe and other countries) is a long-acting injectable formulation of paliperidone palmitoyl ester indicated for once-every 28 days injection after an initial titration period. Paliperidone is used to treat mania and at lower doses as maintenance for bipolar disorder. It is also indicated in the US by the FDA for schizophrenia and schizoaffective disorder.

On May 18, 2015, a new formulation of paliperidone palmitate was approved by the FDA under the brand name Invega Trinza. A similar 3 -monthly injection of prolonged release suspension was approved in 2016 by the European Medicines Agency originally under the brand name Paliperidone Janssen, later renamed to Trevicta.

Most common Paliperidone side effects from eHealthme

• Psychotic disorder - (154 reports)
• Schizophrenia - (123 reports)
• Stress and anxiety - (101 reports)
• Drug ineffective - (93 reports)
• Aggression - (89 reports)
• Agitation - (86 reports)
• Depression - (85 reports)
• Suicidal ideation - (82 reports)
• Suicide attempt - (75 reports)
• Fatigue - (74 reports)

On Jan, 22, 2017   1,629 people reported to have side effects when taking Paliperidone.  Among them, 31 people (1.9%) have Hallucination

On Jan, 18, 2017  1,629 people reported to have side effects when taking Paliperidone. Among them, 47 people (2.89%) have Hallucination, Auditory